Loading...
XKRX
003520
Market cap301mUSD
Jul 11, Last price  
2,270.00KRW
1D
-0.44%
1Q
16.11%
Jan 2017
-74.26%
Name

Yungjin Pharm Co Ltd

Chart & Performance

D1W1MN
P/E
336.77
P/S
1.65
EPS
6.74
Div Yield, %
Shrs. gr., 5y
Rev. gr., 5y
2.71%
Revenues
252.04b
+7.30%
109,659,792,000110,865,010,000103,376,306,000116,317,389,550112,105,475,000137,688,400,340156,622,683,050167,569,401,350170,203,311,310193,133,853,130195,008,846,800186,408,689,480220,516,292,420208,463,639,670196,067,241,850218,380,987,420234,902,460,182252,040,228,760
Net income
1.23b
P
-14,580,311,000-6,733,543,000-4,347,977,000-2,308,665,7302,580,830,0001,794,227,97011,742,329,880909,091,9503,386,324,3304,202,183,1201,867,719,950-6,100,940,1105,029,923,810-133,121,310-11,582,456,190-21,961,039,430-3,875,543,3601,232,792,240
CFO
21.74b
P
-1,338,311,0007,293,678,000-20,150,00010,008,673,3308,496,954,0002,379,190,2905,953,588,4206,216,130,7108,801,551,2303,111,936,5003,151,782,2301,274,179,0809,282,594,81014,497,598,2608,367,764,390-11,609,700,240-12,499,480,14321,740,848,590
Earnings
Jul 30, 2025

Profile

Yungjin Pharm. Co., Ltd. operates as a pharmaceutical company in South Korea. It provides cephalosporin antibiotic, antipsychotic, cardiovascular, and nutrition products. The company was founded in 1952 and is headquartered in Seoul, South Korea. Yungjin Pharm. Co., Ltd. is a subsidiary of KT&G Corporation.
IPO date
Jun 25, 1973
Employees
Domiciled in
KR
Incorporated in
KR

Valuation

Title
KRW in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
252,040,229
7.30%
234,902,460
7.57%
218,380,987
11.38%
Cost of revenue
210,380,265
198,739,556
190,442,318
Unusual Expense (Income)
NOPBT
41,659,964
36,162,904
27,938,670
NOPBT Margin
16.53%
15.39%
12.79%
Operating Taxes
1,654,054
(42,353)
(851,732)
Tax Rate
3.97%
NOPAT
40,005,910
36,205,257
28,790,402
Net income
1,232,792
-131.81%
(3,875,543)
-82.35%
(21,961,039)
89.61%
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
60,451,993
26,014,856
11,735,265
Long-term debt
5,324,848
42,371,430
28,280,886
Deferred revenue
Other long-term liabilities
25,190,478
21,046,154
35,995,160
Net debt
62,340,812
55,557,004
37,440,827
Cash flow
Cash from operating activities
21,740,849
(12,499,480)
(11,609,700)
CAPEX
(21,294,661)
(10,237,537)
(13,200,150)
Cash from investing activities
(18,301,518)
(13,019,745)
(13,352,332)
Cash from financing activities
(7,211,882)
32,044,683
25,179,714
FCF
28,118,058
32,825,920
19,770,780
Balance
Cash
3,436,029
10,207,712
682,254
Long term investments
2,621,570
1,893,071
Excess cash
1,084,158
Stockholders' equity
73,796,540
73,625,753
79,296,672
Invested Capital
180,076,156
176,476,386
165,186,417
ROIC
22.44%
21.19%
17.89%
ROCE
23.13%
20.37%
16.91%
EV
Common stock shares outstanding
182,891
182,892
182,892
Price
1,988.00
-6.45%
2,125.00
-34.62%
3,250.00
-38.56%
Market cap
363,587,511
-6.45%
388,646,465
-34.62%
594,400,476
-38.56%
EV
425,928,323
444,203,469
631,841,302
EBITDA
50,374,757
44,855,710
35,718,627
EV/EBITDA
8.46
9.90
17.69
Interest
5,271,475
2,875,009
736,565
Interest/NOPBT
12.65%
7.95%
2.64%